Physical injury in men after sexual assault: An analysis of 137 cases.

Background: Data on the prevalence of physical injury in men who experience sexual assault are under-represented in the literature; the aim of this study is to inform this knowledge gap. It is vital that forensic examiners have access to up-to-date information regarding the prevalence of genito-anal and extra-genital injury, specific to their examination method (i.e.

Towards a trusted genomics repository: Identifying commercialisation fears and preferred forms of governance across segments of the community.

A latent class analysis on a nationally representative Australian sample ( = 1000) identified four subgroups (i.e. classes), ranging from high to low concern about, and willingness to donate to, a national genomic repository under different forms of public and commercial management and access.

Women attending the sexual assault treatment unit services in the Republic of Ireland: A 7-year review.

Objective: Sexual assault is pervasive in today's society, with the numbers of those reporting it increasing. In Ireland, 50% of women will experience some form of sexual violence in their lifetime. We sought to describe the incident details of females presenting to the Sexual Assault Treatment Unit (SATU) network in the Republic of Ireland and to determine associations between incident characteristics and: (1) victim age, (2) presence of injury, (3) victim-perpetrator relationship, and (4) number of assailants.

Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.

Purpose: The treatment landscape of Oestrogen receptor-positive (ER-positive) breast cancer is evolving, with declining chemotherapy use as a result of Oncotype DX Breast Recurrence Score® testing. Results from the SWOG S1007 RxPONDER trial suggest that adjuvant chemotherapy may benefit some premenopausal women with ER-positive, HER2-negative disease with 1-3 positive lymph nodes (N1), and a Recurrence Score® (RS) of ≤ 25. Postmenopausal women with similar characteristics did not benefit from adjuvant chemotherapy.